Cargando…
Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report
Reactive infectious mucocutaneous eruption is a recently distinguished mucosal-predominant blistering eruption triggered by respiratory infections. We describe a previously healthy 11-year-old Black female with rapidly progressive mucocutaneous blistering after prodromal respiratory infection sympto...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393491/ https://www.ncbi.nlm.nih.gov/pubmed/36003890 http://dx.doi.org/10.1177/2050313X221117887 |
_version_ | 1784771280435675136 |
---|---|
author | Tonkin, Rochelle Ladha, Malika Johnson, Nicole Astle, William F Britton, Ami Shear, Neil H Murguía-Favela, Luis Ramien, Michele |
author_facet | Tonkin, Rochelle Ladha, Malika Johnson, Nicole Astle, William F Britton, Ami Shear, Neil H Murguía-Favela, Luis Ramien, Michele |
author_sort | Tonkin, Rochelle |
collection | PubMed |
description | Reactive infectious mucocutaneous eruption is a recently distinguished mucosal-predominant blistering eruption triggered by respiratory infections. We describe a previously healthy 11-year-old Black female with rapidly progressive mucocutaneous blistering after prodromal respiratory infection symptoms. Reactive infectious mucocutaneous eruption was suspected and treated with systemic corticosteroids followed by etanercept. Twenty-four hours after etanercept, the diagnosis of multisystem inflammatory syndrome in children was raised and intravenous immunoglobulin was given. Rapidly worsening mucocutaneous disease ensued but was controlled by a second dose of etanercept. Our case highlights the following: (1) the novel observation of possible interaction/neutralization of etanercept by intravenous immunoglobulin, (2) the challenging differential diagnosis of multisystem inflammatory syndrome in children for reactive infectious mucocutaneous eruption patients in the Coronavirus disease 2019 (COVID-19) pandemic, and (3) the role of early treatment to prevent dyspigmentation. |
format | Online Article Text |
id | pubmed-9393491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-93934912022-08-23 Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report Tonkin, Rochelle Ladha, Malika Johnson, Nicole Astle, William F Britton, Ami Shear, Neil H Murguía-Favela, Luis Ramien, Michele SAGE Open Med Case Rep JCMS Case Report Reactive infectious mucocutaneous eruption is a recently distinguished mucosal-predominant blistering eruption triggered by respiratory infections. We describe a previously healthy 11-year-old Black female with rapidly progressive mucocutaneous blistering after prodromal respiratory infection symptoms. Reactive infectious mucocutaneous eruption was suspected and treated with systemic corticosteroids followed by etanercept. Twenty-four hours after etanercept, the diagnosis of multisystem inflammatory syndrome in children was raised and intravenous immunoglobulin was given. Rapidly worsening mucocutaneous disease ensued but was controlled by a second dose of etanercept. Our case highlights the following: (1) the novel observation of possible interaction/neutralization of etanercept by intravenous immunoglobulin, (2) the challenging differential diagnosis of multisystem inflammatory syndrome in children for reactive infectious mucocutaneous eruption patients in the Coronavirus disease 2019 (COVID-19) pandemic, and (3) the role of early treatment to prevent dyspigmentation. SAGE Publications 2022-08-17 /pmc/articles/PMC9393491/ /pubmed/36003890 http://dx.doi.org/10.1177/2050313X221117887 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | JCMS Case Report Tonkin, Rochelle Ladha, Malika Johnson, Nicole Astle, William F Britton, Ami Shear, Neil H Murguía-Favela, Luis Ramien, Michele Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report |
title | Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report |
title_full | Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report |
title_fullStr | Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report |
title_full_unstemmed | Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report |
title_short | Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report |
title_sort | reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: a case report |
topic | JCMS Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393491/ https://www.ncbi.nlm.nih.gov/pubmed/36003890 http://dx.doi.org/10.1177/2050313X221117887 |
work_keys_str_mv | AT tonkinrochelle reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport AT ladhamalika reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport AT johnsonnicole reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport AT astlewilliamf reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport AT brittonami reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport AT shearneilh reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport AT murguiafavelaluis reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport AT ramienmichele reactiveinfectiousmucocutaneouseruptionrepeatetanerceptafterintravenousimmunoglobulinacasereport |